FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2054450711> ?p ?o ?g. }

• W2054450711 endingPage "S75" @default.
• W2054450711 startingPage "S75" @default.
• W2054450711 abstract "This study examined the prevalence of potential drug-drug interactions (pDDIs), the impact of pDDIs on healthcare utilization and costs, and post-index use of opioid analgesics among fibromyalgia (FM) Medicare members newly initiated on pregabalin (PGB) or duloxetine (DLX). Members included those with a PGB or DLX prescription claim between 07/01/2008-06/30/2012 (index event), ≥1 inpatient or ≥2 outpatient medical claims with FM diagnosis between 01/01/2008-12/31/2012, and ≥12 months pre-index and ≥6 post-index enrollment. Propensity score matching (nearest neighbor approach) was used to help balance the PGB and DLX cohorts on baseline demographic and comorbidity characteristics. pDDIs were defined based on Micromedex 2.0 software and were identified by prescription claims. Six month post-index healthcare utilization and costs were measured by medical and pharmacy claims. Continuous and categorical comparisons were conducted using Wilcoxon rank sum tests and chi-square tests, respectively. No significant differences in baseline demographics or comorbidities were found between matched PGB (n=794) and DLX members (n=794). pDDI prevalence was significantly greater (p<0.0001) among DLX members (71.9%) than among PGB members (4.0%). There were no significant differences in all-cause healthcare utilization or costs between PGB members with and without a pDDI. By contrast, DLX members with a pDDI had higher median all-cause costs ($4,719 versus $3,519; p<0.0001) and median number of outpatient visits/member (14.0 versus 12.0; p=0.0009) in comparison to DLX members without a pDDI. Over 12% of potential DLX interactions involved anticoagulants (n=268). There was a trend toward a difference between PGB and DLX members in their respective pre-versus-post differences in use of long-acting opioids (1.6% and 3.4%, respectively; p=0.077). The significantly higher prevalence of pDDIs and potential cost impact found in FM DLX users, relative to PGB, underscore the importance of considering DDIs when selecting a treatment. This study was funded by Pfizer Inc and Humana Inc. This study examined the prevalence of potential drug-drug interactions (pDDIs), the impact of pDDIs on healthcare utilization and costs, and post-index use of opioid analgesics among fibromyalgia (FM) Medicare members newly initiated on pregabalin (PGB) or duloxetine (DLX). Members included those with a PGB or DLX prescription claim between 07/01/2008-06/30/2012 (index event), ≥1 inpatient or ≥2 outpatient medical claims with FM diagnosis between 01/01/2008-12/31/2012, and ≥12 months pre-index and ≥6 post-index enrollment. Propensity score matching (nearest neighbor approach) was used to help balance the PGB and DLX cohorts on baseline demographic and comorbidity characteristics. pDDIs were defined based on Micromedex 2.0 software and were identified by prescription claims. Six month post-index healthcare utilization and costs were measured by medical and pharmacy claims. Continuous and categorical comparisons were conducted using Wilcoxon rank sum tests and chi-square tests, respectively. No significant differences in baseline demographics or comorbidities were found between matched PGB (n=794) and DLX members (n=794). pDDI prevalence was significantly greater (p<0.0001) among DLX members (71.9%) than among PGB members (4.0%). There were no significant differences in all-cause healthcare utilization or costs between PGB members with and without a pDDI. By contrast, DLX members with a pDDI had higher median all-cause costs ($4,719 versus $3,519; p<0.0001) and median number of outpatient visits/member (14.0 versus 12.0; p=0.0009) in comparison to DLX members without a pDDI. Over 12% of potential DLX interactions involved anticoagulants (n=268). There was a trend toward a difference between PGB and DLX members in their respective pre-versus-post differences in use of long-acting opioids (1.6% and 3.4%, respectively; p=0.077). The significantly higher prevalence of pDDIs and potential cost impact found in FM DLX users, relative to PGB, underscore the importance of considering DDIs when selecting a treatment. This study was funded by Pfizer Inc and Humana Inc." @default.
• W2054450711 created "2016-06-24" @default.
• W2054450711 creator A5023291539 @default.
• W2054450711 creator A5030523303 @default.
• W2054450711 creator A5031146373 @default.
• W2054450711 creator A5042073172 @default.
• W2054450711 creator A5064892797 @default.
• W2054450711 creator A5075274424 @default.
• W2054450711 creator A5082251142 @default.
• W2054450711 creator A5082429921 @default.
• W2054450711 date "2014-04-01" @default.
• W2054450711 modified "2023-09-23" @default.
• W2054450711 title "(398) Potential drug-drug interactions and opioid use among Medicare members with fibromyalgia and newly initiated on pregabalin or duloxetine" @default.
• W2054450711 doi "https://doi.org/10.1016/j.jpain.2014.01.309" @default.
• W2054450711 hasPublicationYear "2014" @default.
• W2054450711 type Work @default.
• W2054450711 sameAs 2054450711 @default.
• W2054450711 citedByCount "0" @default.
• W2054450711 crossrefType "journal-article" @default.
• W2054450711 hasAuthorship W2054450711A5023291539 @default.
• W2054450711 hasAuthorship W2054450711A5030523303 @default.
• W2054450711 hasAuthorship W2054450711A5031146373 @default.
• W2054450711 hasAuthorship W2054450711A5042073172 @default.
• W2054450711 hasAuthorship W2054450711A5064892797 @default.
• W2054450711 hasAuthorship W2054450711A5075274424 @default.
• W2054450711 hasAuthorship W2054450711A5082251142 @default.
• W2054450711 hasAuthorship W2054450711A5082429921 @default.
• W2054450711 hasBestOaLocation W20544507111 @default.
• W2054450711 hasConcept C118552586 @default.
• W2054450711 hasConcept C126322002 @default.
• W2054450711 hasConcept C142724271 @default.
• W2054450711 hasConcept C160735492 @default.
• W2054450711 hasConcept C162324750 @default.
• W2054450711 hasConcept C204787440 @default.
• W2054450711 hasConcept C2426938 @default.
• W2054450711 hasConcept C2776291444 @default.
• W2054450711 hasConcept C2776468701 @default.
• W2054450711 hasConcept C2777831278 @default.
• W2054450711 hasConcept C2778829437 @default.
• W2054450711 hasConcept C2778858636 @default.
• W2054450711 hasConcept C2780764818 @default.
• W2054450711 hasConcept C50522688 @default.
• W2054450711 hasConcept C71924100 @default.
• W2054450711 hasConcept C98274493 @default.
• W2054450711 hasConceptScore W2054450711C118552586 @default.
• W2054450711 hasConceptScore W2054450711C126322002 @default.
• W2054450711 hasConceptScore W2054450711C142724271 @default.
• W2054450711 hasConceptScore W2054450711C160735492 @default.
• W2054450711 hasConceptScore W2054450711C162324750 @default.
• W2054450711 hasConceptScore W2054450711C204787440 @default.
• W2054450711 hasConceptScore W2054450711C2426938 @default.
• W2054450711 hasConceptScore W2054450711C2776291444 @default.
• W2054450711 hasConceptScore W2054450711C2776468701 @default.
• W2054450711 hasConceptScore W2054450711C2777831278 @default.
• W2054450711 hasConceptScore W2054450711C2778829437 @default.
• W2054450711 hasConceptScore W2054450711C2778858636 @default.
• W2054450711 hasConceptScore W2054450711C2780764818 @default.
• W2054450711 hasConceptScore W2054450711C50522688 @default.
• W2054450711 hasConceptScore W2054450711C71924100 @default.
• W2054450711 hasConceptScore W2054450711C98274493 @default.
• W2054450711 hasIssue "4" @default.
• W2054450711 hasLocation W20544507111 @default.
• W2054450711 hasOpenAccess W2054450711 @default.
• W2054450711 hasPrimaryLocation W20544507111 @default.
• W2054450711 hasRelatedWork W1500932720 @default.
• W2054450711 hasRelatedWork W2006293098 @default.
• W2054450711 hasRelatedWork W2016656115 @default.
• W2054450711 hasRelatedWork W2068144313 @default.
• W2054450711 hasRelatedWork W2117021343 @default.
• W2054450711 hasRelatedWork W2226648823 @default.
• W2054450711 hasRelatedWork W2287282505 @default.
• W2054450711 hasRelatedWork W2910374806 @default.
• W2054450711 hasRelatedWork W4293238736 @default.
• W2054450711 hasRelatedWork W3143127967 @default.
• W2054450711 hasVolume "15" @default.
• W2054450711 isParatext "false" @default.
• W2054450711 isRetracted "false" @default.
• W2054450711 magId "2054450711" @default.
• W2054450711 workType "article" @default.